Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A04203 | 33716447 | World J Gastroenterol | G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment. | 2021 | Details |
| A04204 | 33716004 | Metabolism | Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. | 2021 | Details |
| A04207 | 33713358 | Hepatology | TNF-α-Induce Protein 8-Like 1 Inhibits Hepatic Steatosis, Inflammation, and Fibrosis by Suppressing Polyubiquitination of Apoptosis Signal-Regulating Kinase 1. | 2021 | Details |
| A04213 | 33711479 | Clin Gastroenterol Hepatol | Treatment Candidacy for Pharmacologic Therapies for NASH. | 2021 | Details |
| A04216 | 33709875 | Expert Rev Gastroenterol Hepatol | Telomerase: a key player in the pathogenesis of non-alcoholic fatty liver disease? | 2021 | Details |
| A04218 | 33709607 | J Gastroenterol Hepatol | Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis. | 2021 | Details |
| A04219 | 33709606 | J Gastroenterol Hepatol | Artificial intelligence in precision medicine in hepatology. | 2021 | Details |
| A04221 | 33709477 | J Gastroenterol Hepatol | Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. | 2021 | Details |
| A04223 | 33708783 | Front Med (Lausanne) | Diagnosis of Fibrosis Using Blood Markers and Logistic Regression in Southeast Asian Patients With Non-alcoholic Fatty Liver Disease. | 2021 | Details |
| A04224 | 33708352 | World J Hepatol | Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us? | 2021 | Details |
| A04229 | 33706839 | Epidemiol Psychiatr Sci | Depression and increased risk of non-alcoholic fatty liver disease in individuals with obesity. | 2021 | Details |
| A04242 | 33692781 | Front Immunol | Increased Frequency of Dysfunctional Siglec-7-CD57+PD-1+ Natural Killer Cells in Patients With Non-alcoholic Fatty Liver Disease. | 2021 | Details |
| A04244 | 33692700 | Front Physiol | Characterization of the CDAA Diet-Induced Non-alcoholic Steatohepatitis Model: Sex-Specific Differences in Inflammation, Fibrosis, and Cholesterol Metabolism in Middle-Aged Mice. | 2021 | Details |
| A04245 | 33691757 | Diabetol Metab Syndr | Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. | 2021 | Details |
| A04249 | 33690979 | Small | Bioengineered Multicellular Liver Microtissues for Modeling Advanced Hepatic Fibrosis Driven Through Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A04251 | 33689215 | J Cell Mol Med | Inhibition of miR-188-5p alleviates hepatic fibrosis by significantly reducing the activation and proliferation of HSCs through PTEN/PI3K/AKT pathway. | 2021 | Details |
| A04252 | 33688490 | Can J Gastroenterol Hepatol | Association between Gastroesophageal Reflux Disease and Elastographic Parameters of Liver Steatosis and Fibrosis: Controlled Attenuation Parameter and Liver Stiffness Measurements. | 2021 | Details |
| A04257 | 33686111 | Sci Rep | A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. | 2021 | Details |
| A04259 | 33685807 | Dig Liver Dis | Liver fibrosis assessed by transient elastography is independently associated with albuminuria in the general United States population. | 2021 | Details |
| A04268 | 33683797 | Int J Clin Pract | The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross-sectional study. | 2021 | Details |
| A04271 | 33681089 | Can J Gastroenterol Hepatol | NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. | 2021 | Details |
| A04273 | 33680428 | Hepat Oncol | Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma. | 2020 | Details |
| A04277 | 33679803 | Front Immunol | Revisiting the Role of Natural Killer Cells in Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A04282 | 33679045 | J Clin Exp Hepatol | Comparison of Elastography Point Quantification with Transient Elastography in Patients with Chronic Viral Hepatitis and Nonalcoholic Fatty Liver Disease: A Pilot Study. | 2020 | Details |
| A04286 | 33677935 | Endocrinol Metab (Seoul) | Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes. | 2021 | Details |
| A04288 | 33676874 | Surg Obes Relat Dis | The metabolic and liver-related outcomes of bariatric surgery in adult patients with insulin-treated type 2 diabetes and nonalcoholic fatty liver disease at high risk of liver fibrosis. | 2020 | Details |
| A04291 | 33675475 | Int Urol Nephrol | Prevalence of non-alcoholic fatty liver disease among patients with non-diabetic chronic kidney disease detected by transient elastography. | 2021 | Details |
| A04294 | 33673227 | Nutrients | Temporal Development of Dyslipidemia and Nonalcoholic Fatty Liver Disease (NAFLD) in Syrian Hamsters Fed a High-Fat, High-Fructose, High-Cholesterol Diet. | 2021 | Details |
| A04295 | 33673113 | Biomedicines | Natural Progression of Non-Alcoholic Steatohepatitis to Hepatocellular Carcinoma. | 2021 | Details |
| A04296 | 33673073 | Int J Mol Sci | Effect of Chronic Western Diets on Non-Alcoholic Fatty Liver of Male Mice Modifying the PPAR-γ Pathway via miR-27b-5p Regulation. | 2021 | Details |
| A04297 | 33672887 | Toxins (Basel) | Fungi-Bacteria Correlation in Alcoholic Hepatitis Patients. | 2021 | Details |
| A04298 | 33672864 | Life (Basel) | FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. | 2021 | Details |
| A04312 | 33669443 | J Clin Med | Roles of Ceramides in Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A04315 | 33668153 | Cancers (Basel) | MicroRNA-21 Plays Multiple Oncometabolic Roles in the Process of NAFLD-Related Hepatocellular Carcinoma via PI3K/AKT, TGF-β, and STAT3 Signaling. | 2021 | Details |
| A04316 | 33668077 | J Gastroenterol Hepatol | Systematic review: Accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis. | 2021 | Details |
| A04321 | 33665755 | Obes Surg | Decision Tree for the Performance of Intraoperative Liver Biopsy During Bariatric Surgery. | 2021 | Details |
| A04322 | 33665589 | JHEP Rep | From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management? | 2021 | Details |
| A04328 | 33664397 | Sci Rep | Hepatic lymphocytes involved in the pathogenesis of pediatric and adult non-alcoholic fatty liver disease. | 2021 | Details |
| A04330 | 33664289 | Sci Rep | Clodronate, an inhibitor of the vesicular nucleotide transporter, ameliorates steatohepatitis and acute liver injury. | 2021 | Details |
| A04332 | 33664007 | Arab J Gastroenterol | Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome. | 2021 | Details |
| A04333 | 33662773 | Clin Res Hepatol Gastroenterol | Low levels of Lysosomal Acid Lipase (LAL) activity increases necroinflammation in adult patients with biopsy-proven metabolic associated fatty liver disease. | 2021 | Details |
| A04336 | 33659890 | JHEP Rep | Case-finding strategies in non-alcoholic fatty liver disease. | 2020 | Details |
| A04338 | 33658534 | Sci Rep | Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men. | 2021 | Details |
| A04340 | 33658438 | Endocr J | Association between serum 25-hydroxy vitamin D level and metabolic associated fatty liver disease (MAFLD)-a population-based study. | 2021 | Details |
| A04342 | 33657584 | J Hypertens | Blood pressure, glycemic status and advanced liver fibrosis assessed by transient elastography in the general United States population. | 2021 | Details |
| A04343 | 33657443 | Contemp Clin Trials | The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. | 2021 | Details |
| A04345 | 33656663 | Hepatol Int | Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease. | 2021 | Details |
| A04346 | 33655500 | Br J Pharmacol | Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. | 2021 | Details |
| A04357 | 33648885 | Obes Res Clin Pract | Comparison between non-invasive methods and liver histology to stratify liver fibrosis in obese patients submitted to bariatric surgery. | 2021 | Details |
| A04361 | 33647884 | Aging (Albany NY) | Exercise in mice ameliorates high-fat diet-induced nonalcoholic fatty liver disease by lowering HMGCS2. | 2021 | Details |
| A04364 | 33647584 | Cytokine | Lipid-injured hepatocytes release sOPN to improve macrophage migration via CD44 engagement and pFak-NFκB signaling. | 2021 | Details |
| A04365 | 33647502 | Ann Hepatol | The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population. | 2021 | Details |
| A04367 | 33647205 | Chem Res Toxicol | LXRα/β Antagonism Protects against Lipid Accumulation in the Liver but Increases Plasma Cholesterol in Rhesus Macaques. | 2021 | Details |
| A04368 | 33644233 | Biomed Res Int | Plateletcrit and Mean Platelet Volume in the Evaluation of Alcoholic Liver Cirrhosis and Nonalcoholic Fatty Liver Disease Patients. | 2021 | Details |
| A04371 | 33643221 | Front Endocrinol (Lausanne) | Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis. | 2021 | Details |
| A04373 | 33642832 | World J Gastroenterol | Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort. | 2021 | Details |
| A04374 | 33642826 | World J Gastroenterol | Prevalence of advanced liver fibrosis and steatosis in type-2 diabetics with normal transaminases: A prospective cohort study. | 2021 | Details |
| A04376 | 33642551 | Biol Pharm Bull | Deletion of TRPC3 or TRPC6 Fails to Attenuate the Formation of Inflammation and Fibrosis in Non-alcoholic Steatohepatitis. | 2021 | Details |
| A04383 | 33640303 | Dig Liver Dis | Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the Atherosclerosis Risk in Communities Study. | 2021 | Details |
| A04388 | 33638902 | Hepatology | Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer. | 2021 | Details |
| A04389 | 33638251 | J Gastroenterol Hepatol | Community screening identifies undiagnosed chronic liver disease in high-risk populations. | 2021 | Details |
| A04393 | 33636655 | Clin Res Hepatol Gastroenterol | Prevalence and clinical characteristics of alpha-1 antitrypsin deficiency in liver explants in a Mexican cohort. | 2021 | Details |
| A04396 | 33635729 | Br J Radiol | Quantitative magnetic resonance imaging for chronic liver disease. | 2021 | Details |
| A04398 | 33633748 | Front Immunol | Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease. | 2021 | Details |
| A04400 | 33632710 | Gut | From the origin of NASH to the future of metabolic fatty liver disease. | 2021 | Details |
| A04402 | 33632113 | Endocr Metab Immune Disord Drug Targets | Effects of Metformin-Single Therapy on the Level of Inflammatory Markers in Serum of Non-Obese T2DM Patients with NAFLD. | 2022 | Details |
| A04403 | 33632105 | Curr HIV Res | Transient Elastography in HIV Infected Patients with Liver Steatosis Identifies a High-Risk Group for Non-Alcoholic Steatohepatitis. | 2021 | Details |
| A04405 | 33631228 | J Hepatol | Targeting cell-intrinsic metabolism for antifibrotic therapy. | 2021 | Details |
| A04410 | 33629536 | Mol Nutr Food Res | Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial. | 2021 | Details |
| A04411 | 33628759 | Can J Gastroenterol Hepatol | Assessment of Steatosis and Fibrosis in Liver Transplant Recipients Using Controlled Attenuation Parameter and Liver Stiffness Measurements. | 2021 | Details |
| A04414 | 33628193 | Front Pharmacol | Fructose and Non-Alcoholic Steatohepatitis. | 2021 | Details |
| A04422 | 33622266 | BMC Gastroenterol | The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C. | 2021 | Details |
| A04424 | 33622003 | Ultraschall Med | Diagnostic Value of Ultrasound in Fatty Liver Disease. | 2021 | Details |
| A04426 | 33620426 | Biosci Biotechnol Biochem | Development of a novel mouse model of diet-induced nonalcoholic steatohepatitis-related progressive bridging fibrosis. | 2021 | Details |
| A04436 | 33616848 | Obes Surg | Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A04439 | 33616043 | J Diabetes Complications | Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years. | 2020 | Details |
| A04446 | 33613940 | Frontline Gastroenterol | Evaluation of a primary to secondary care referral pathway and novel nurse-led one-stop clinic for patients with suspected non-alcoholic fatty liver disease. | 2020 | Details |
| A04448 | 33612679 | Intern Med | Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study. | 2021 | Details |
| A04450 | 33612037 | Expert Rev Clin Pharmacol | Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. | 2021 | Details |
| A04456 | 33609303 | Hepatology | Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling. | 2021 | Details |
| A04460 | 33608033 | Nutr Metab (Lond) | Fat mass to fat-free mass ratio and the risk of non-alcoholic fatty liver disease and fibrosis in non-obese and obese individuals. | 2021 | Details |
| A04461 | 33606661 | Eur J Endocrinol | Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study. | 2021 | Details |
| A04462 | 33606428 | J Clin Gastroenterol | Effect of Statin Use on Cancer-related Mortality in Nonalcoholic Fatty Liver Disease: A Prospective United States Cohort Study. | 2022 | Details |
| A04466 | 33604254 | J Clin Transl Hepatol | Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. | 2020 | Details |
| A04468 | 33604250 | J Clin Transl Hepatol | Systematic Review and Meta-analysis of Circulating Fetuin-A Levels in Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A04472 | 33603757 | Front Immunol | Extracellular Vesicles as Inflammatory Drivers in NAFLD. | 2021 | Details |
| A04475 | 33602617 | J Diabetes Complications | Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis. | 2021 | Details |
| A04476 | 33602481 | Clin Res Hepatol Gastroenterol | A pragmatic non-invasive assessment of liver fibrosis in patients with psoriasis, rheumatoid arthritis or Crohn's disease receiving methotrexate therapy. | 2020 | Details |
| A04479 | 33601216 | Nutr Res | G protein-coupled receptors: Key molecules in metabolic associated fatty liver disease development. | 2020 | Details |
| A04481 | 33601024 | Endocr Pract | Association Between Non-Alcoholic Fatty Liver Disease and Diabetes-Related Microvascular Complications: A Retrospective Cross-Sectional Study of Hospitalized Patients. | 2021 | Details |
| A04482 | 33600604 | J Gastroenterol Hepatol | Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model. | 2021 | Details |
| A04488 | 33598647 | JHEP Rep | Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD. | 2020 | Details |
| A04490 | 33598084 | Pan Afr Med J | Interest of hepatic steatosis index (HSI) in screening for metabolic steatopathy in patients with type 2 diabetes. | 2020 | Details |
| A04491 | 33597924 | Front Endocrinol (Lausanne) | The Role of Lipophagy in the Development and Treatment of Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A04495 | 33596938 | J Transl Med | Insulin treatment improves liver histopathology and decreases expression of inflammatory and fibrogenic genes in a hyperglycemic, dyslipidemic hamster model of NAFLD. | 2021 | Details |
| A04502 | 33595214 | Isr Med Assoc J | The Impact of Ramadan Fasting on Fatty Liver Disease Severity: A Retrospective Case Control Study from Israel. | 2021 | Details |
| A04504 | 33594747 | Hepatol Res | Artificial intelligence/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. | 2021 | Details |
| A04506 | 33594581 | Diabetes Ther | Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial. | 2021 | Details |
| A04513 | 33592427 | Clin Res Hepatol Gastroenterol | Integrated expression profiles of mRNA and miRNA in a gerbil model of fatty liver fibrosis treated with exenatide. | 2021 | Details |
| A04514 | 33592199 | Life Sci | Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. | 2021 | Details |